- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 1, Pages 23
Publisher
MDPI AG
Online
2018-01-22
DOI
10.3390/cancers10010023
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
- (2017) James J. Hsieh et al. EUROPEAN UROLOGY
- OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC)
- (2017) Sara Pilotto et al. Journal of Thoracic Oncology
- Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
- (2017) John K. Simmons et al. MOLECULAR CANCER THERAPEUTICS
- Marked for death: targeting epigenetic changes in cancer
- (2017) Sophia Xiao Pfister et al. NATURE REVIEWS DRUG DISCOVERY
- Twenty-five years of mTOR: Uncovering the link from nutrients to growth
- (2017) David M. Sabatini PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study
- (2017) Fleur Weeber et al. Oncotarget
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities
- (2017) Claudio Pulito et al. Cell Discovery
- PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
- (2017) Michele Milella et al. Scientific Reports
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers
- (2016) M. Morrison Joly et al. CANCER RESEARCH
- Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches
- (2016) Katarzyna Switon et al. IUBMB LIFE
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Epigenomic regulation of oncogenesis by chromatin remodeling
- (2016) R Kumar et al. ONCOGENE
- mTORC1 and mTORC2 in cancer and the tumor microenvironment
- (2016) L C Kim et al. ONCOGENE
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
- (2016) I. Ben-Sahra et al. SCIENCE
- The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
- (2016) Peter Tan et al. Oncotarget
- Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
- (2016) Yu Liu et al. Oncotarget
- Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
- (2016) Sun Min Lim et al. Oncotarget
- The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway
- (2016) Lioubov G. Korotchkina et al. Aging-US
- Therapeutic potential of mTOR inhibitors for targeting cancer stem cells
- (2015) Maria Giovanna Francipane et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy
- (2015) A. M. Eiden et al. CLINICAL CANCER RESEARCH
- A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma
- (2015) Ravindran Kanesvaran et al. Clinical Genitourinary Cancer
- Drugging PI3K in cancer: refining targets and therapeutic strategies
- (2015) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
- (2015) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis
- (2015) Teguh Haryo Sasongko et al. Orphanet Journal of Rare Diseases
- Intersection of mTOR and STAT signaling in immunity
- (2015) Diana Saleiro et al. TRENDS IN IMMUNOLOGY
- Current treatment strategies for inhibiting mTOR in cancer
- (2015) Francesca Chiarini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
- (2015) H. Cheng et al. Cancer Discovery
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
- (2015) P. Liu et al. Cancer Discovery
- PTEN: Multiple Functions in Human Malignant Tumors
- (2015) Michele Milella et al. Frontiers in Oncology
- mLST8 Promotes mTOR-Mediated Tumor Progression
- (2015) Kyoko Kakumoto et al. PLoS One
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
- (2014) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations
- (2014) M Moschetta et al. BRITISH JOURNAL OF PHARMACOLOGY
- mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels
- (2014) Kaveh M Goudarzi et al. CANCER BIOLOGY & THERAPY
- Rapamycin: One Drug, Many Effects
- (2014) Jing Li et al. Cell Metabolism
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms
- (2014) John K. Simmons et al. Molecular Oncology
- Autophagy, p53, and Pancreatic Cancer
- (2014) Christine A. Iacobuzio-Donahue et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
- (2014) Nikhil Wagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1 signaling controls multiple steps in ribosome biogenesis
- (2014) Valentina Iadevaia et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- NF- B, an Active Player in Human Cancers
- (2014) Y. Xia et al. Cancer Immunology Research
- Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer
- (2013) Parvin F. Peddi et al. CANCER TREATMENT REVIEWS
- Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology
- (2013) Venus Thomanetz et al. JOURNAL OF CELL BIOLOGY
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- p53 status determines the role of autophagy in pancreatic tumour development
- (2013) Mathias T. Rosenfeldt et al. NATURE
- Signals from the lysosome: a control centre for cellular clearance and energy metabolism
- (2013) Carmine Settembre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
- (2013) ELENI ANDRIANA TRIGKA et al. ONCOLOGY REPORTS
- mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
- (2013) Costanza Bogani et al. PLoS One
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
- (2013) M. Weiler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
- (2013) S. A. Kang et al. SCIENCE
- A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1
- (2013) L. Bar-Peled et al. SCIENCE
- Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
- (2013) Mary E. Peterson SUPPORTIVE CARE IN CANCER
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- Role of PRAS40 in Akt and mTOR signaling in health and disease
- (2012) Claudia Wiza et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model
- (2012) Cun Wang et al. BMC CANCER
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
- (2012) F. Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
- (2012) Alejandro Gomez-Pinillos et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas
- (2012) Penelope Korkolopoulou et al. HISTOPATHOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms
- (2012) Ludovica Ciuffreda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1
- (2012) Christian C. Dibble et al. MOLECULAR CELL
- mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake
- (2012) Ömer H. Yilmaz et al. NATURE
- PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12
- (2012) Xiaoqing Gan et al. NATURE CELL BIOLOGY
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
- (2012) Lise Willems et al. Current Oncology Reports
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
- (2011) Ana M. Molina et al. CANCER
- mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways
- (2011) P. Gulhati et al. CANCER RESEARCH
- mTOR complex 2 signaling and functions
- (2011) Won Jun Oh et al. CELL CYCLE
- A Central Role for mTOR Kinase in Homeostatic Proliferation Induced CD8+ T Cell Memory and Tumor Immunity
- (2011) Qingsheng Li et al. IMMUNITY
- Convergence of the Mammalian Target of Rapamycin Complex 1- and Glycogen Synthase Kinase 3- -Signaling Pathways Regulates the Innate Inflammatory Response
- (2011) H. Wang et al. JOURNAL OF IMMUNOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Regulation of mTORC1 Complex Assembly and Signaling by GRp58/ERp57
- (2011) I. Ramirez-Rangel et al. MOLECULAR AND CELLULAR BIOLOGY
- Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size
- (2011) Abdelhafid Saci et al. MOLECULAR CELL
- mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR
- (2011) Daming Gao et al. MOLECULAR CELL
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- The mTOR Pathway: A New Target in Cancer Therapy
- (2010) L. Ciuffreda et al. CURRENT CANCER DRUG TARGETS
- New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
- (2010) Sébastien Albert et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The mTOR Kinase Determines Effector versus Memory CD8 + T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin
- (2010) Rajesh R. Rao et al. IMMUNITY
- Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity
- (2010) Lei Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly
- (2010) Takeshi Kaizuka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation
- (2010) M. Haidinger et al. JOURNAL OF IMMUNOLOGY
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
- (2010) Katrin Düvel et al. MOLECULAR CELL
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
- (2010) T Sato et al. ONCOGENE
- Paradoxical suppression of cellular senescence by p53
- (2010) Z. N. Demidenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
- (2009) M. G. Kharas et al. BLOOD
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
- (2009) David A. Guertin et al. CANCER CELL
- Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors
- (2009) J. Huang et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging
- (2009) Rogerio M. Castilho et al. Cell Stem Cell
- ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
- (2009) Ian G. Ganley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
- (2009) Nao Hosokawa et al. MOLECULAR BIOLOGY OF THE CELL
- ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
- (2009) Chang Hwa Jung et al. MOLECULAR BIOLOGY OF THE CELL
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Hsp70 associates with Rictor and is required for mTORC2 formation and activity
- (2008) Jheralyn Martin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
- (2008) Jingxiang Huang et al. BIOCHEMICAL JOURNAL
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells
- (2008) M. Ohtani et al. BLOOD
- Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
- (2008) Audrey Carrière et al. CURRENT BIOLOGY
- Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling
- (2008) M. P. DeYoung et al. GENES & DEVELOPMENT
- TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species
- (2008) Chong Chen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
- (2008) K Kojima et al. LEUKEMIA
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
- (2008) Y. Sancak et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now